Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSH | P09668 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20953393 | 0.96 | HRH3 (0.38) | HRH3DPP4ACHECTSLCTSB | |
| SCHEMBL9925438 | 0.88 | KCNH2 (0.36) | KCNH2CYP2D6 | |
| SCHEMBL102379 | 0.86 | HRH3 (0.42) | HRH3KCNH2CYP2D6 | |
| SCHEMBL198169 | 0.78 | — | — | |
| SCHEMBL170562 | 0.78 | — | — | |
| SCHEMBL13253252 | 0.77 | HRH3 (0.39) | HRH3KCNH2 | |
| SCHEMBL21636914 | 0.77 | NCF1 (0.45) | HRH3DPP4ACHECTSLCTSB | |
| SCHEMBL16376644 | 0.77 | HRH3 (0.39) | HRH3KCNH2 | |
| SCHEMBL1117894 | 0.77 | ALDH1A1 (0.34) | HRH3ACHEKCNH2CYP2D6 | |
| SCHEMBL21934638 | 0.76 | HRH3 (0.35) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | HRH3 2014/4885DPP4 3672/4885ACHE 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.